Advertisement

Cytomegalovirus and the Eye

  • Marc D. de Smet
Part of the Essentials in Ophthalmology book series (ESSENTIALS)

Keywords

Optic Neuritis Occlude Branch Retinal Vein Cytomegalovirus Retinitis Oral Ganciclovir Cotton Wool Spot 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jabs DA, van Natta ML, Kempen JH, et al. (2002) Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 133:48–61CrossRefPubMedGoogle Scholar
  2. 2.
    Jabs DA, Enger C, Bartlett JG (1989) Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 107:75–80PubMedGoogle Scholar
  3. 3.
    van den Horn GJ, Meenken C, Danner SA, et al. (1998) Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol 82:988–990PubMedGoogle Scholar
  4. 4.
    Lin DY, Warren JF, Lazzeroni LC, et al. (2002) Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV-infected patients. Natural history and clinical predictors. Retina 22:268–277CrossRefPubMedGoogle Scholar
  5. 5.
    Lilleri D, Piccinini G, Baldanti F, et al. (2003) Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response. J Clin Virol 26:95–100CrossRefPubMedGoogle Scholar
  6. 6.
    Torriani FJ, Freeman WR, Macdonald JC, et al. (2000) CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 14:1041–1049PubMedGoogle Scholar
  7. 7.
    Salmon-Ceron D, Mazeron MC, Chaput S, et al. (2000) Plasma cytomegalovirus DNA, pp65 antigenemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 14:1041–1049PubMedGoogle Scholar
  8. 8.
    Kempen JH, Jabs DA, Wilson LA, et al. (2003) Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 37:1365–1373CrossRefPubMedGoogle Scholar
  9. 9.
    Fishburne BC, Micrani AA, Davis JL (1998) Cytomegalovirus retinitis after cardiac transplantation. Am J Ophthalmol 125:104–106PubMedGoogle Scholar
  10. 10.
    Shibolet O, Ilan Y, Kalish Y, et al. (2003) Late cytomegalovirus disease following liver transplantation. Transpl Int 16:861–865CrossRefPubMedGoogle Scholar
  11. 11.
    Machado CM, Menezes RX, Macedo MC (2001) Extended antigenemia surveillance and late cytomegalovirus infection after allogeneic BMT. Bone Marrow Transplant 28:1053PubMedGoogle Scholar
  12. 12.
    Agrawal A, Dick AD, Olson JA (2003) Visual symptoms in patients on cyclophosphamide may herald sight threatening disease. Br J Ophthalmol 87:122–123CrossRefPubMedGoogle Scholar
  13. 13.
    Palestine AG, Polis MA, de Smet MD, et al. (1991) A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 115:665–673PubMedGoogle Scholar
  14. 14.
    Holbrook JT, Davis MD, Hubbard LD, et al. (2000) Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 118:1196–1204PubMedGoogle Scholar
  15. 15.
    de Smet MD, Nussenblatt RB (1991) Ocular manifestations of AIDS. J Am Med Assoc 266:3019–3022CrossRefGoogle Scholar
  16. 16.
    Spaide RF, Vitale AT, Toth IR, et al. (1992) Frosted branch angiitis with cytomegalovirus retinitis. Am J Ophthalmol 113:522–528PubMedGoogle Scholar
  17. 17.
    Grossniklaus HE, Frank KE, Tomsak RL (1987) Cytomegalovirus retinitis and optic neuritis in acquired immune deficiency syndrome. Ophthalmology 94:1601–1604PubMedGoogle Scholar
  18. 18.
    Meenken C, van den Horn GJ, van der Meer JTM, et al. (1998) Optic neuritis heralding varicella zoster virus retinitis in a patient with AIDS. Ann Neurol 43:534–536CrossRefPubMedGoogle Scholar
  19. 19.
    de Smet MD, De Fen S, Pepose JS, et al. (2003) Microdissection combined with the polymerase chain reaction to identify potentiating viral coinfection in patients with HIV/AIDS with ocular infection. Can J Ophthalmol 38:207–213PubMedGoogle Scholar
  20. 20.
    de Boer JH, Verhagen C, Bruinenberg M, et al. (1996) Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmol 121:650–658PubMedGoogle Scholar
  21. 21.
    Doornenbal P, Baarsma GS, Quint WGV, et al. (1996) Diagnostic assays in cytomegalovirus retinitis: detection of herpes virus by simultaneous application of the polymerase chain reaction and local antibody analysis on ocular fluid. Br J Ophthalmol 80:235–240PubMedGoogle Scholar
  22. 22.
    Ando Y, Terao K, Narita M, et al. (2002) Quantitative analyses of cytomegalovirus genome in aqueous humor of patients with cytomegalovirus retinitis. Jpn J Ophthalmol 46:254–260CrossRefPubMedGoogle Scholar
  23. 23.
    Scholz M, Doerr HW, Cinatl J (2003) Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol 11:171–178PubMedGoogle Scholar
  24. 24.
    Jabs DA, Martin BK, Forman MS, et al. (2003) Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol 135:26–34CrossRefPubMedGoogle Scholar
  25. 25.
    Martin DF, Kuppermann BD, Wolitz RA, et al. (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 340:1063–1070CrossRefPubMedGoogle Scholar
  26. 26.
    Cochereau-Massin I, LeHoang P, Lautie-Frau M, et al. (1991) Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 98:1348–1353PubMedGoogle Scholar
  27. 27.
    Baudouin C, Gastaud P (1992) A modified procedure for intravitreal injections of ganciclovir in the treatment of cytomegalovirus retinitis. Ophthalmology 99:1183Google Scholar
  28. 28.
    Young SH, Morlet N, Heery S, et al. (1992) High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 157:370–373PubMedGoogle Scholar
  29. 29.
    Martin DF, Dunn JP, Davis JL, et al. (1999) Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society — USA Panel. Am J Ophthalmol 127:329–339CrossRefPubMedGoogle Scholar
  30. 30.
    Martin DF, Parks DJ, Mellow SD, et al. (1994) Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Arch Ophthalmol 112:1531–1539PubMedGoogle Scholar
  31. 31.
    Martin DF, Sierra-Madero J, Walmsley S, et al. (2002) A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346:1119–1126CrossRefPubMedGoogle Scholar
  32. 32.
    Weinberg A, Jabs DA, Chou S, et al. (2003) Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 187:777–784CrossRefPubMedGoogle Scholar
  33. 33.
    Cytomegalovirus Retreatment Trial (1996) Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 114:23–33Google Scholar
  34. 34.
    Butler KM, de Smet MD, Husson RN, et al. (1992) Treatment of aggressive CMV retinitis with ganciclovir in combination with foscarnet in a child with human immunodeficiency virus infection. J Pediatr 120:483–485PubMedGoogle Scholar
  35. 35.
    Berthe P, Baudouin C, Garraffo R, et al. (1994) Toxicologic and pharmacokinetic analysis of intravitreal injections of foscarnet, either alone or in combination with ganciclovir. Invest Ophthalmol Vis Sci 35:1038–1045PubMedGoogle Scholar
  36. 36.
    De Clercq E (2003) Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 16:569–596CrossRefPubMedGoogle Scholar
  37. 37.
    Lalezari JP, Holland GN, Kramer F, et al. (1998) Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 17:339–344PubMedGoogle Scholar
  38. 38.
    Berenguer J, Mallolas J, Spanish Cidofovir Study Group (2000) Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Clin Infect Dis 30:182–184CrossRefPubMedGoogle Scholar
  39. 39.
    Banker AS, Arevalo JF, Munguia D, et al. (1997) Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol 124:168–180PubMedGoogle Scholar
  40. 40.
    de Smet MD, Meenken C, van den Horn GJ (1999) Fomivirsen: a phosphorothioate oligonucleotide for the treatment of cytomegalovirus retinitis. Ocul Immunol Infl 7:189–198CrossRefGoogle Scholar
  41. 41.
    Vitravene Study Group (2002) Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 133:475–483Google Scholar
  42. 42.
    Vitravene Study Group (2002) A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133:467–474Google Scholar
  43. 43.
    Vitravene Study Group (2002) Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133:484–498Google Scholar
  44. 44.
    Goldberg DE, Wang H, Azen SP, et al. (2003) Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol 87:853–855CrossRefPubMedGoogle Scholar
  45. 45.
    Stone SF, Price P, Tay-Kearney ML, et al. (2002) Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy — induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 185:1813–1817CrossRefPubMedGoogle Scholar
  46. 46.
    Kempen JH, Jabs DA, Dunn JP, et al. (2001) Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol 119:33–40PubMedGoogle Scholar
  47. 47.
    Holland GN, Buhles WC, Mastre B, et al. (1989) A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Arch Ophthalmol 107:1759–1766PubMedGoogle Scholar
  48. 48.
    Drew WL, Ives D, Lalezari JP, et al. (1995) Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N Engl J Med 333:615–620CrossRefPubMedGoogle Scholar
  49. 49.
    Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group (2000) Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMOC peripheral cytomegalovirus retinitis trial. AIDS 14:1571–1581Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Marc D. de Smet

There are no affiliations available

Personalised recommendations